Skip to main content


Figure 2 | Thrombosis Journal

Figure 2

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Figure 2

Tornado diagram of net monetary benefit of rivaroxaban versus LMWH/VKA. Patients requiring 6 months of anticoagulation. DVT, deep vein thrombosis; GP, general practitioner; HR, hazard ratio; LMWH, low molecular weight heparin; OP, outpatient; OWSA, one-way sensitivity analysis; PE, pulmonary embolism; QALY, quality-adjusted life-year; VKA, vitamin K antagonist; VTE, venous thromboembolism.

Back to article page